Ekso Bionics Raises $5.3M via Convertible Preferred Stock Offering
EKSO has more than doubled off its 52-week low of $2.73.
Summary
Ekso Bionics finalized a $5.3 million private placement, issuing convertible preferred stock and warrants to institutional investors. The proceeds will be used for working capital and general corporate purposes.
Key Events · Financing and Capital Events · EKSO
-
Private Placement Completed
Ekso Bionics closed a private placement, issuing Series B Convertible Preferred Stock and warrants, raising approximately $5.3 million after fees.
-
Proceeds Allocated
The company intends to use the net proceeds for working capital and general corporate purposes.
-
Registration Rights Agreement
Ekso Bionics has agreed to file a registration statement for the resale of conversion shares and warrant shares by June 1, 2026.
Analysis · EKSO · Technology
Ekso Bionics secured $5.3 million through a private placement, issuing Series B Convertible Preferred Stock and warrants. This capital infusion will support working capital and general corporate needs. The offering includes warrants and preferred stock redeemable after one year, suggesting a need for capital but also offering potential returns to investors.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EKSO was trading at $7.90 on NASDAQ in the Technology sector, with a market capitalization of approximately $26.8M. The 52-week trading range was $2.73 to $12.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.